[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1524971T3 - Forbedret transdermalt leveringssystem - Google Patents

Forbedret transdermalt leveringssystem

Info

Publication number
DK1524971T3
DK1524971T3 DK03766330T DK03766330T DK1524971T3 DK 1524971 T3 DK1524971 T3 DK 1524971T3 DK 03766330 T DK03766330 T DK 03766330T DK 03766330 T DK03766330 T DK 03766330T DK 1524971 T3 DK1524971 T3 DK 1524971T3
Authority
DK
Denmark
Prior art keywords
functional drug
amine functional
matrix
drug
tds
Prior art date
Application number
DK03766330T
Other languages
Danish (da)
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1524971T3 publication Critical patent/DK1524971T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03766330T 2002-07-30 2003-07-28 Forbedret transdermalt leveringssystem DK1524971T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
DK1524971T3 true DK1524971T3 (da) 2007-02-19

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03766330T DK1524971T3 (da) 2002-07-30 2003-07-28 Forbedret transdermalt leveringssystem

Country Status (22)

Country Link
EP (2) EP1386604A1 (ja)
JP (1) JP4837915B2 (ja)
KR (1) KR101016914B1 (ja)
CN (1) CN100558350C (ja)
AT (1) ATE343380T1 (ja)
AU (1) AU2003266252B2 (ja)
BR (1) BR0313092A (ja)
CA (1) CA2490573C (ja)
CY (1) CY1105878T1 (ja)
DE (1) DE60309329T2 (ja)
DK (1) DK1524971T3 (ja)
ES (1) ES2273042T3 (ja)
HK (1) HK1083458A1 (ja)
IL (1) IL165917A (ja)
MX (1) MXPA05000349A (ja)
NO (1) NO334187B1 (ja)
NZ (1) NZ537476A (ja)
PL (1) PL376999A1 (ja)
PT (1) PT1524971E (ja)
SI (1) SI1524971T1 (ja)
WO (1) WO2004012719A1 (ja)
ZA (1) ZA200500255B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2009107479A1 (ja) * 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
WO2009107478A1 (ja) * 2008-02-27 2009-09-03 久光製薬株式会社 貼付剤及び包装体
BR112012017737A8 (pt) * 2009-12-22 2018-04-17 Lts Lohmann Therapie Systeme Ag polivinilpirrolidona para a estabilização de uma dispersão sólida da forma não cristalina de rotigotina.
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
EP1381352B1 (en) * 2001-03-16 2007-06-13 Alza Corporation Transdermal patch for administering fentanyl
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
EP1325742A1 (en) * 2001-05-08 2003-07-09 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
CA2490573A1 (en) 2004-02-12
NO20050770L (no) 2005-02-11
AU2003266252A1 (en) 2004-02-23
SI1524971T1 (sl) 2007-02-28
IL165917A0 (en) 2006-01-15
ZA200500255B (en) 2006-01-25
DE60309329T2 (de) 2008-04-17
AU2003266252B2 (en) 2008-11-20
CA2490573C (en) 2011-06-07
CN100558350C (zh) 2009-11-11
KR20050025638A (ko) 2005-03-14
NO334187B1 (no) 2014-01-13
PL376999A1 (pl) 2006-01-23
WO2004012719A1 (en) 2004-02-12
HK1083458A1 (en) 2006-07-07
EP1524971A1 (en) 2005-04-27
EP1524971B1 (en) 2006-10-25
NZ537476A (en) 2007-08-31
BR0313092A (pt) 2005-06-21
EP1386604A1 (en) 2004-02-04
JP4837915B2 (ja) 2011-12-14
CN1671365A (zh) 2005-09-21
MXPA05000349A (es) 2005-03-31
IL165917A (en) 2007-07-24
KR101016914B1 (ko) 2011-02-22
CY1105878T1 (el) 2011-02-02
ES2273042T3 (es) 2007-05-01
DE60309329D1 (de) 2006-12-07
ATE343380T1 (de) 2006-11-15
JP2005535686A (ja) 2005-11-24
PT1524971E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
HK1083458A1 (en) Improved transdermal delivery system
DK1524975T3 (da) Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin
DK1418894T3 (da) Transdermalt terapeutisk system med fentanyl
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
NO20001003L (no) Transdermalt terapeutisk system omfattende et trykksensitivt adhesivt reservoarsjikt og et unidireksjonalt elastisk dekksjikt
DE60314298D1 (de) Therapeutisches pflaster mit capsaicin-haltiger polysiloxan-matrix
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK1251853T3 (da) Transdermalt terapeutisk system til indgivelse af zaleplon
DK1011674T3 (da) Transdermalt terapeutisk system indeholdende det aktive stof af scopolaminbase
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
DE50313224D1 (de) Pflaster, enthaltend Fentanylum